DGX - Quest Diagnostics Incorporated

NYSE - NYSE Delayed Price. Currency in USD
89.24
-0.38 (-0.42%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close89.62
Open89.49
Bid82.00 x 900
Ask92.47 x 900
Day's Range88.50 - 90.44
52 Week Range78.95 - 116.49
Volume1,284,776
Avg. Volume1,323,406
Market Cap11.982B
Beta (3Y Monthly)0.95
PE Ratio (TTM)16.87
EPS (TTM)5.29
Earnings DateApr 23, 2019
Forward Dividend & Yield2.12 (2.37%)
Ex-Dividend Date2019-01-14
1y Target Est94.59
Trade prices are not sourced from all markets
  • Quest Diagnostics (DGX) Up 3.5% Since Last Earnings Report: Can It Continue?
    Zacks7 days ago

    Quest Diagnostics (DGX) Up 3.5% Since Last Earnings Report: Can It Continue?

    Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Should Value Investors Pick Quest Diagnostics (DGX) Stock?
    Zacks9 days ago

    Should Value Investors Pick Quest Diagnostics (DGX) Stock?

    Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Quest Diagnostics Inc.

    Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold DGX had net inflows of $3.73 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. DGX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Oxford Immunotec Global PLC (OXFD) Q4 2018 Earnings Conference Call Transcript
    Motley Fool12 days ago

    Oxford Immunotec Global PLC (OXFD) Q4 2018 Earnings Conference Call Transcript

    OXFD earnings call for the period ending December 31, 2018.

  • Quest Diagnostics Prices $500 Million of Senior Notes
    PR Newswire16 days ago

    Quest Diagnostics Prices $500 Million of Senior Notes

    SECAUCUS, N.J., March 7, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $500 million aggregate principal amount of its 4.200% senior notes due 2029 under the Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to receive the net offering proceeds upon closing on March 12, 2019, subject to customary closing conditions.  The company intends to use the net proceeds from the offering to repay outstanding indebtedness, which includes the $300 million aggregate principal amount of its senior notes due April 2019, and indebtedness under its secured receivables credit facility, and for general corporate purposes. This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

  • Moody's16 days ago

    Quest Diagnostics Incorporated -- Moody's assigns Baa2 rating to Quest Diagnostics' notes offering

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.

  • Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
    PR Newswire16 days ago

    Quest Diagnostics To Speak At The Barclays Global Healthcare Conference

    SECAUCUS, N.J., March 7, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • Quest Diagnostics Ties Up With RMC to Deliver Lab Services
    Zacks18 days ago

    Quest Diagnostics Ties Up With RMC to Deliver Lab Services

    Quest Diagnostic's (DGX) partnership with RMC is set to better the quality of patient care.

  • Should Quest Diagnostics Be Disappointed With Their 64% Profit?
    Simply Wall St.19 days ago

    Should Quest Diagnostics Be Disappointed With Their 64% Profit?

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significantRead More...

  • Quest Diagnostics Declares Quarterly Cash Dividend
    PR Newswire22 days ago

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J. , March 1, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...

  • RMC and Quest Diagnostics to Deliver High-Value, Innovative Lab Services
    PR Newswire24 days ago

    RMC and Quest Diagnostics to Deliver High-Value, Innovative Lab Services

    SECAUCUS , N.J. and ORANGEBURG, S.C. , Feb. 27, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Regional Medical Center (RMC) of ...

  • Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
    Zacks29 days ago

    Quest Diagnostics Grows on Innovation Amid Reimbursement Woe

    Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.

  • GlobeNewswire29 days ago

    Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GuruFocus.comlast month

    Quest Diagnostics Inc (DGX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. The dividend yield of Quest Diagnostics Inc stocks is 2.30%. Quest Diagnostics Inc had annual average EBITDA growth of 3.00% over the past ten years.

  • Quest Diagnostics Partners With Houston Healthcare to Deliver High-Value, Innovative Laboratory Services
    PR Newswirelast month

    Quest Diagnostics Partners With Houston Healthcare to Deliver High-Value, Innovative Laboratory Services

    SECAUCUS, N.J. and WARNER ROBINS, Ga., Feb. 20, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.

  • Quest Diagnostics Elects Denise Morrison to Board of Directors
    PR Newswirelast month

    Quest Diagnostics Elects Denise Morrison to Board of Directors

    SECAUCUS, N.J., Feb. 19, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019.  Including Ms. Morrison, the company's Board has 11 members. Ms. Morrison served as President and Chief Executive Officer of Campbell Soup Company from 2011 to 2018. "In addition to her broad management experiences, Denise has a deep understanding of the consumer market and will bring a helpful new perspective as Quest pursues its strategy to be the most consumer-oriented diagnostic information services provider," said Steve Rusckowski, Chairman, CEO and President.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of DGX earnings conference call or presentation 14-Feb-19 1:30pm GMT

    Q4 2018 Quest Diagnostics Inc Earnings Call

  • Quest Diagnostics Names Gabrielle Wolfson Senior Vice President and Chief Information and Digital Officer
    PR Newswirelast month

    Quest Diagnostics Names Gabrielle Wolfson Senior Vice President and Chief Information and Digital Officer

    SECAUCUS, N.J., Feb. 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today that Gabrielle Wolfson, a veteran information technology business leader, has been named Senior Vice President and Chief Information and Digital Officer. Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. "Gabrielle is a dynamic business and technology leader with a proven record of harnessing technology and data to create strong businesses and engaged, loyal customers," said Mr. Rusckowski.

  • How Much Are Quest Diagnostics Incorporated (NYSE:DGX) Insiders Taking Off The Table?
    Simply Wall St.last month

    How Much Are Quest Diagnostics Incorporated (NYSE:DGX) Insiders Taking Off The Table?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...

  • Quest Diagnostics Inc (DGX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Quest Diagnostics Inc (DGX) Q4 2018 Earnings Conference Call Transcript

    DGX earnings call for the period ending December 31, 2018.

  • Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
    Zackslast month

    Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

    In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

  • Quest Diagnostics (DGX) Q4 Earnings Meet Estimates
    Zackslast month

    Quest Diagnostics (DGX) Q4 Earnings Meet Estimates

    Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Quest Diagnostics: 4Q Earnings Snapshot

    On a per-share basis, the Secaucus, New Jersey-based company said it had net income of 92 cents. Earnings, adjusted for one-time gains and costs, came to $1.36 per share. The results met Wall Street expectations. ...

  • Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019
    PR Newswirelast month

    Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019

    - Fourth quarter revenues of $1.84 billion , down 1.4% versus 2017 - Fourth quarter diluted EPS of $0.92 on a reported basis, down 49.5% from 2017 which included a tax benefit recorded as a result of the ...

  • TheStreet.comlast month

    Quest Diagnostics Expected to Earn $1.37 a Share

    is expected to report earnings of $1.37 a share on sales of $1.9 billion before the market opens Feb. 14, based on a FactSet survey of 17 analysts. The stock has fallen 6.3% since the company last reported earnings on Oct. 23. Quest Diagnostics is currently trading at a price-to-forward-earnings ratio of 13.6 based on the 12-month estimates of 19 analysts surveyed by FactSet.